Gland Pharma Stock Price Analysis and Quick Research Report. Is Gland Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Gland Pharma. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Gland Pharma has a PE ratio of 29.3115725023457 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Gland Pharma has ROA of 10.9179% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Gland Pharma has a Current ratio of 11.0106.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Gland Pharma has a ROE of 11.6247%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Gland Pharma has a Debt to Equity ratio of 0.0003 which means that the company has low proportion of debt in its capital.

• Sales growth: Gland Pharma has reported revenue growth of -1.2305% which is poor in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Gland Pharma for the current financial year is 35.0477594469977%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Gland Pharma is Rs 18 and the yield is 0.8911%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Gland Pharma is Rs 68.9557. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Gland Pharma in Ticker for free. Also, one can get the intrinsic value of Gland Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Gland Pharma FAQs

Q1. What is Gland Pharma share price today?
Ans: The current share price of Gland Pharma is Rs 2021.2.

Q2. What is the market capitalisation of Gland Pharma?
Ans: Gland Pharma has a market capitalisation of Rs 33300.56821676 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Gland Pharma?
Ans: The PE ratio of Gland Pharma is 29.3115725023457 and the P/B ratio of Gland Pharma is 3.32198174980935, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Gland Pharma share?
Ans: The 52-week high share price of Gland Pharma is Rs 2131, and the 52-week low share price of Gland Pharma is Rs 1277.8.

Q5. Does Gland Pharma pay dividends?
Ans: Currently, Gland Pharma pays dividends. Dividend yield of Gland Pharma is around 0.8911%.

Q6. What are the face value and book value of Gland Pharma shares?
Ans: The face value of Gland Pharma shares is Rs 1, while the book value per share of Gland Pharma is around Rs 608.432. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Gland Pharma?
Ans: Gland Pharma has a total debt of Rs 2.551 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Gland Pharma?
Ans: The ROE of Gland Pharma is 11.6247% and ROCE of Gland Pharma is 15.8713%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Gland Pharma a good buy for the long term?
Ans: The Gland Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Gland Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Gland Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Gland Pharma’s financials?
Ans: You can review Gland Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.